MSWA
CMPX icon

Marshall & Sterling Wealth Advisors’s Compass Therapeutics CMPX Stock Holding History

Marshall & Sterling Wealth Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438 Hold
200
– – ﹤0.01% 320
2026
Q1 		$1.06K Hold
200
– – ﹤0.01% 309
2025
Q4 		$1.07K Hold
200
– – ﹤0.01% 305
2025
Q3 		$700 Hold
200
– – ﹤0.01% 612
2025
Q2 		$520 Hold
200
– – ﹤0.01% 607
2025
Q1 		$380 Hold
200
– – ﹤0.01% 623
2024
Q4 		$290 Buy
+200
New +$332 ﹤0.01% 350

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall & Sterling Wealth Advisors's CMPX Position: Q2 2026 in Review

Marshall & Sterling Wealth Advisors held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 200 shares worth $438. The position accounts for ﹤0.01% of the portfolio, ranked #320.

Marshall & Sterling Wealth Advisors first reported a position in CMPX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.07K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Marshall & Sterling Wealth Advisors held 200 shares of Compass Therapeutics worth $438 as of Q2 2026.
  • Marshall & Sterling Wealth Advisors left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Marshall & Sterling Wealth Advisors's portfolio in Q2 2026, its #320 holding.
  • Marshall & Sterling Wealth Advisors first reported a position in Compass Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Marshall & Sterling Wealth Advisors's Compass Therapeutics position peaked at $1.07K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Marshall & Sterling Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.